OCX - OncoCyte Corporation
| Previous Close | 3.5200 |
| Open | 3.5600 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 800 |
| Day's Range | 3.6600 - 3.8300 |
| 52 Week Range | 1.1000 - 6.9200 |
| Volume | 76,995 |
| Avg. Volume | 1,308,676 |
| Market Cap | 192.299M |
| Beta (3Y Monthly) | 6.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4280 |
| Earnings Date | Mar 25, 2019 - Mar 28, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.15 |
- Yahoo Finance Video•2 months ago
OncoCyte soars after promising results from its cancer detection tests
Biotech company OncoCyte is using a liquid biopsy to detect lung cancer that is showing promising results. Yahoo Finance’s Alexis Christoforous speaks to William Annett, the CEO of Oncocyte.
- Markit•6 days ago
See what the IHS Markit Score report has to say about OncoCyte Corp.
OncoCyte Corp NYSE MKT:OCXView full report here! Summary * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is extremely low for OCX with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting OCX. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold OCX had net inflows of $402 million over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- GlobeNewswire•12 days ago
OncoCyte Corporation to Present at Cowen and Company 39th Annual Health Care Conference in Boston
ALAMEDA, Calif., March 06, 2019 -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that.
- GlobeNewswire•14 days ago
OncoCyte Announces Initiation of Analytical Validation Study
OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced the initiation of the Company’s Analytical Validation study of DetermaVu™ Lung, its liquid biopsy test for lung cancer. Having recently achieved very positive results from its R&D Validation study, OncoCyte is now working to complete the remaining development studies required for commercialization of DetermaVu™, including Analytical Validation, CLIA Validation and Clinical Validation.
- GlobeNewswire•last month
BioTime Provides Business Update Including Information on AgeX, OncoCyte and Asterias
BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today provided a business update which included information on AgeX Therapeutics, Inc. (AgeX) (NYSE American: AGE) and BioTime’s two affiliated companies, OncoCyte Corporation (OncoCyte) (NYSE American: OCX), and Asterias Biotherapeutics, Inc. (Asterias) (NYSE American: AST). “In the past five months, BioTime has made rapid progress toward its commitment to become a leading cell therapy company by focusing on clinical-stage cell therapy product candidates with promising human data and supporting their development in part through targeted transactions among its affiliated companies,” stated Brian M. Culley, Chief Executive Officer of BioTime, Inc.
- GlobeNewswire•last month
OncoCyte Announces Closing of Public Offering of Common Stock
OncoCyte Corporation (NYSE American: OCX) (“OncoCyte”), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, today announced the closing of an underwritten public offering. Following the exercise in full by the underwriters of their option to purchase up to an additional 1,400,000 shares of common stock at the public offering price, OncoCyte sold 10,733,334 shares of its common stock at a public offering price of $3.75 per share, for aggregate gross proceeds of approximately $40.25 million, from the Company’s existing shelf registration statement. OncoCyte intends to use the net proceeds of the public offering to support its DetermaVuTM commercialization efforts and additional clinical studies to support reimbursement and adoption, to initiate future product development, and for general corporate and working capital purposes.
- GlobeNewswire•last month
OncoCyte Announces Pricing of Public Offering of Common Stock
OncoCyte Corporation (NYSE American: OCX) (“OncoCyte”), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, today announced the pricing of an underwritten public offering of 9,333,334 shares of its common stock at a public offering price of $3.75 per share, for aggregate gross proceeds of approximately $35 million. OncoCyte has granted the underwriters a 30-day option to purchase up to an additional 1,400,000 shares of common stock at the public offering price to cover over-allotments, if any. OncoCyte intends to use the net proceeds of the public offering to support its DetermaVuTM commercialization efforts and additional clinical studies to support reimbursement and adoption, to initiate future product development, and for general corporate and working capital purposes.
- GlobeNewswire•last month
OncoCyte Announces Proposed Public Offering of Common Stock
OncoCyte Corporation (NYSE American: OCX) (“OncoCyte”), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares of common stock to be sold in the offering will be offered by OncoCyte. Piper Jaffray is acting as the sole book-running manager and Janney Montgomery Scott is acting as the co-manager for the public offering. OncoCyte intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering on the same terms and conditions, to cover over-allotments, if any.
- Motley Fool•2 months ago
Here's Why OncoCyte Is Giving Back Some Gains Today
A bit of profit taking after huge gains yesterday is pressuring the liquid biopsy developer.
- ACCESSWIRE•2 months ago
Has OncoCyte Changed How We Will Diagnose Cancer in the Near Future?
NEW YORK, NY / ACCESSWIRE / January 30, 2019 / Traders News Source, a leading independent equity researchand corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...
- ACCESSWIRE•2 months ago
Today's Research Reports on Trending Tickers: Amgen and OncoCyte
NEW YORK, NY / ACCESSWIRE / January 30, 2019 / U.S. markets were mostly down Tuesday on the latest batch of corporate earnings and as investors await details from the Feds' two-day policy meeting. The ...
- ACCESSWIRE•2 months ago
These 4 Healthcare Stocks Healthy With Potential Opportunities
With headlines popping up left and right, news surrounding these innovative companies in the healthcare industry has worked to attract investors looking for potential opportunities in the space. Premier Health Group (OTC:PHGRF) (CSE:PHGI), OncoCyte Corp (NYSE American: OCX), Neovasc Inc (NVCN), Zynerba Pharmaceuticals Inc (ZYNE) represent four healthcare companies working tirelessly to champion treatment solutions for the betterment of humankind. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company focused on developing nuanced approaches that combine human skill-based expertise with state-of-the-art technologies used throughout the healthcare industry to create the best-possible care solutions for their growing patient network.
- MarketWatch•2 months ago
OncoCyte upgraded to buy at Janney on high hopes for lung cancer biopsy test
Shares of OncoCyte Corp. soared more than 200% on Tuesday after the developer of cancer detection tests reported positive results from a trial of a new biopsy test of lung cancer. Janney analyst Paul Knight upgraded the stock to buy and raised his fair-value target to $8, or 37% above its current trading level. "Oncocyte's novel technology in the compelling lung cancer market is proving to be a diagnostic breakthrough for the largest cancer diagnostic market with the largest unmet need," Night wrote in a note. OncoCyte said the validation study of its DetermaVu liquid test showed sensitivity of 90%, which is the percentage of malignant nodules that are correctly identified, and specificity of 75%, which is the percentage of benign nodules correctly identified. The company "has taken the most critical step to commercialization, which we expect will occur in the second half," said Knight. The study result significantly outperforms any other blinded study of its kind "and signifies the first blood based test on the market to use strictly biomarkers for cancer detection," he wrote. "We view that DetermaVu's estimated annual addressable market of $4.7 billion." Shares are now up 316% in 2019, while the S&P 500 has gained 5%.
- MarketWatch•2 months ago
OncoCyte's stock doubles on heavy volume after positive results of cancer detection test
Shares of OncoCyte Corp. more than doubled in very active premarket trade Tuesday, after the developer of cancer detection tests reported positive results from its validation study of its DetermaVu liquid biopsy test for lung cancer. The stock ran up 104% on volume of about 820,000 shares, compared with the full-day average volume of about 30,350 shares. The company said the DetermaVu study demonstrated sensitivity of 90%, which is the percentage of malignant nodules that are correctly identified, and specificity of 75%, which is the percentage of benign nodules correctly identified. "These results show that DetermaVuTM significantly exceeds the critical parameters necessary for use in lung cancer diagnosis and that DetermaVu clearly outperforms reported results from competitors' tests and other clinical models," OncoCyte said in a statement. "DetermaVu™ has the potential to dramatically reduce U.S. healthcare costs by billions of dollars each year by eliminating unnecessary biopsies, which, according to a recent Medicare study, cost on average $14,634 each." The company expects DetermaVu to be commercially available in the second half of 2019. The stock has tumbled 54% over the past 12 months through Monday, while the S&P 500 has lost 7.4%.
- GlobeNewswire•2 months ago
OncoCyte Announces Successful Results of DetermaVu™ R&D Validation Study
The R&D Validation study demonstrated a sensitivity of 90% (95% CI 82%-95%) and specificity of 75% (95% CI 68%-81%) of DetermaVu™ on a prospectively collected cohort of 250 patient blood samples that were blinded to laboratory operators. Sensitivity is the percentage of malignant nodules that are correctly identified and specificity is the percentage of benign nodules correctly identified.
- GlobeNewswire•2 months ago
OncoCyte Schedules Announcement and Conference Call to Discuss Results from Key R&D Validation Study of DetermaVu™
ALAMEDA, Calif, Jan. 28, 2019 -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today scheduled an.
- GlobeNewswire•2 months ago
OncoCyte Announces Transition to Ion Torrent Next-Generation Sequencing Platform
OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced its successful transition to the Ion GeneStudio S5 next-generation sequencing (NGS) platform for targeted sequencing. The platform was chosen by OncoCyte after evaluating four leading platforms. OncoCyte anticipates that the use of the Ion GeneStudio S5 System will increase the likelihood that DetermaVu™ will offer the consistent and robust results necessary for product development and further studies.
- GlobeNewswire•3 months ago
OncoCyte Provides Progress Update on Ongoing Studies
OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that it has run all of the 700 samples required for its Algorithm Development Study, which is intended to derive the proprietary mathematical algorithm that will be used to interpret the results of the DetermaVu™ assay. The data from the samples is being analyzed by biostatisticians who are developing the algorithm, and once completed and optimized, OncoCyte will use the algorithm to carry out its R&D Validation study. The Company has also run the 250 blinded, prospectively-collected patient blood samples to be used for its R&D Validation study, which is designed to confirm the performance of the proprietary algorithm on a blinded set of samples.
- GlobeNewswire•4 months ago
Report: Developing Opportunities within Summit Midstream Partners, LP, Empire State Realty Trust, Expeditors International of Washington, Ellington Residential Mortgage REIT, OncoCyte, and Sachem Capital — Future Expectations, Projections Moving into 2018
NEW YORK, Nov. 26, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
